Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Li Auto Inc (LI) Price & Performance

ARK Genomic Revolution ETFTrade
Li Auto IncTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Li Auto Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.31, while Li Auto Inc trades at $12.6 (market cap $12.54B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.

ARKGLI
Sector
Sector/ThematicConsumer Cyclical
52-Week High
$44.55$26.69
52-Week Low
$24.02$11.74
Market Cap
$12.54B
Enterprise Value
$1.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.

The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.

Li Auto Inc

Li Auto (LI) trades at $12.95, up 2.05% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries show modest growth, with 30,468 vehicles delivered in July 2026. Analyst consensus remains divided with a $14.80 price target, suggesting potential upside from current levels despite near-term challenges.

The outlook for LI is cautious with revenue contraction and profitability pressures, though the EV market in China offers long-term growth potential. Key risks include intense domestic competition and execution challenges with new vehicle launches. Investment opportunity exists if the company can stabilize margins and regain growth momentum, supported by analyst optimism for recovery from 2027 onwards.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Li Auto Inc

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.

Read more on LI